These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 17112802

  • 1. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
    Benowitz NL, Swan GE, Jacob P, Lessov-Schlaggar CN, Tyndale RF.
    Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
    Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL.
    Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
    Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF.
    Eur J Clin Pharmacol; 2006 Jun; 62(6):481-4. PubMed ID: 16758265
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine.
    Hukkanen J, Gourlay SG, Kenkare S, Benowitz NL.
    Clin Pharmacol Ther; 2005 Mar; 77(3):159-69. PubMed ID: 15735610
    [Abstract] [Full Text] [Related]

  • 9. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
    Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R.
    Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
    [Abstract] [Full Text] [Related]

  • 10. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
    Swan GE, Benowitz NL, Lessov CN, Jacob P, Tyndale RF, Wilhelmsen K.
    Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
    [Abstract] [Full Text] [Related]

  • 11. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
    Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF.
    Nicotine Tob Res; 2003 Dec; 5(6):891-9. PubMed ID: 14668073
    [Abstract] [Full Text] [Related]

  • 12. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
    Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF.
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
    [Abstract] [Full Text] [Related]

  • 13. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
    Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P, Tyndale RF, Swan GE, Benowitz NL.
    Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
    [Abstract] [Full Text] [Related]

  • 14. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
    Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K.
    Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
    [Abstract] [Full Text] [Related]

  • 15. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
    Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T.
    Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
    [Abstract] [Full Text] [Related]

  • 16. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
    Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T.
    Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
    [Abstract] [Full Text] [Related]

  • 17. Metabolism and disposition kinetics of nicotine.
    Hukkanen J, Jacob P, Benowitz NL.
    Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
    [Abstract] [Full Text] [Related]

  • 18. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
    Zhang X, Ameno K, Ameno S, Kinoshita H, Kubota T, Kumihashi M, Mostofa J, Iwahashi K, Ijiri I.
    Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of nicotine and its metabolites I. Model development.
    Levi M, Dempsey DA, Benowitz NL, Sheiner LB.
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):5-21. PubMed ID: 17206524
    [Abstract] [Full Text] [Related]

  • 20. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
    Nakajima M, Yokoi T.
    Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.